Next Article in Journal
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
Next Article in Special Issue
Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies
Previous Article in Journal
Glutathione in Cancer Cell Death
Previous Article in Special Issue
Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers
Cancers 2011, 3(1), 1311-1328; doi:10.3390/cancers3011311

Cancer Stem Cells in Breast Cancer

1 Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan 2 Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 Shikata-cho, Okayama City, Okayama 700-8558, Japan
* Author to whom correspondence should be addressed.
Received: 17 February 2011 / Revised: 3 March 2011 / Accepted: 11 March 2011 / Published: 15 March 2011
(This article belongs to the Special Issue Cancer Stem Cells)
View Full-Text   |   Download PDF [381 KB, uploaded 15 March 2011]   |   Browse Figure


The cancer stem cell (CSC) theory is generally acknowledged as an important field of cancer research, not only as an academic matter but also as a crucial aspect of clinical practice. CSCs share a variety of biological properties with normal somatic stem cells in self-renewal, the propagation of differentiated progeny, the expression of specific cell markers and stem cell genes, and the utilization of common signaling pathways and the stem cell niche. However, CSCs differ from normal stem cells in their chemoresistance and their tumorigenic and metastatic activities. In this review, we focus on recent reports regarding the identification of CSC markers and the molecular mechanism of CSC phenotypes to understand the basic properties and molecular target of CSCs. In addition, we especially focus on the CSCs of breast cancer since the use of neoadjuvant chemotherapy can lead to the enrichment of CSCs in patients with that disease. The identification of CSC markers and an improved understanding of the molecular mechanism of CSC phenotypes should lead to progress in cancer therapy and improved prognoses for patients with cancer.
Keywords: cancer stem cells; breast cancer; EMT; TGF-b; microRNAs cancer stem cells; breast cancer; EMT; TGF-b; microRNAs
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Takahashi, R.-U.; Takeshita, F.; Fujiwara, T.; Ono, M.; Ochiya, T. Cancer Stem Cells in Breast Cancer. Cancers 2011, 3, 1311-1328.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert